Old Targets Are Crowded, but They Can Still Make Money

This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers.

Core Thesis

An old target is not automatically a bad target. It becomes unattractive only when the new product cannot explain why it deserves a place against existing therapies. Differentiation may come from convenience, safety, combination logic, biomarker segmentation, or market access.

Why It Matters

The business lesson is that novelty and value are not the same thing. Investors should ask whether a company has a clear wedge into an existing market, not whether the mechanism sounds brand new.

Reading Framework

Drugnews reads this topic through five practical questions:

• What new evidence or business signal has actually changed?
• Which risks remain unresolved in clinical development, CMC, regulation, or commercialization?
• Does the event improve strategic optionality for partnership, licensing, financing, or M&A?
• Can the company convert scientific progress into durable market position?
• Does the information change valuation, or only create short-term attention?

What To Watch Next

Readers should watch for follow-up data, trial design changes, safety signals, regulatory feedback, manufacturing readiness, payer response, competitive readouts, partnership activity, and whether management can turn the story into measurable execution.

Original Chinese Edition

This English page is designed to make Drugnews analysis searchable and readable for English-language audiences while preserving the Chinese original as the primary source edition.

Read the original Chinese article: 老靶點都很捲，但不是不能賺錢

This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.